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anary Prostate Active Surveillance
tudy: Design of a Multi-institutional
ctive Surveillance Cohort and Biorepository
isa F. Newcomb, James D. Brooks, Peter R. Carroll, Ziding Feng, Martin E. Gleave,
eter S. Nelson, Ian M. Thompson, and Daniel W. Lin
ctive surveillance is a management plan for localized prostate cancer that offers selective delayed intervention on
ndication of disease progression, allowing patients to delay or avoid treatment and associated side-effects. Outcomes
rom centers that promote active surveillance are favorable, with high rates of disease-specific survival. However, there
emains a need for prognostic variables or biomarkers that distinguish with high specificity the aggressive cancers that
rogress on surveillance from the indolent cancers. The Canary Prostate Active Surveillance Study is a multicenter
tudy and a biorepository that will discover and confirm biomarkers of aggressive disease as defined by histologic,
rostate-specific antigen, or clinical criteria. UROLOGY 75: 407–413, 2010. © 2010 Elsevier Inc.
r
t
t
s
p
r
d
t
b
c
m
n
R
O
c
o
c
i
g
p
a
e
n
u
m
i
fi
p
m
l
b
n
Open access under CC BY-NC-ND license. rostate cancer is a heterogeneous disease. Al-
though various clinical and pathologic parameters
are associated with prostate cancer progression and
ecurrence, the natural history of localized prostate can-
er is not completely understood. Prostate cancer is the
ost commonly diagnosed cancer among men in the
nited States, and the second leading cause of cancer
ortality,1 although there is clear evidence that a signif-
cant percentage of prostate cancers existing in the pop-
lation will never become clinically evident or cause
ortality. Autopsy studies have demonstrated that ap-
roximately 1 in 3 men aged  50 years has histologic
vidence of prostate cancer, but up to 80% of the tumors
re small in size ( 0.5 cm) and low in grade, suggesting
hey are clinically insignificant.2 Furthermore, compari-
ons of autopsy-detected prostate cancer rates before and
fter prostate-specific antigen (PSA) testing was intro-
uced, showing a decrease in prevalence after PSA test-
ng became widely used.3 These data are concordant with
tudies comparing prostate cancer mortality in the ab-
ence and presence of PSA screening, which suggest
idespread use of PSA screening may be at least in part
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2010 Elsevier Inc. Open access under CC BY-NC-ND license. esponsible for the decrease in mortality because of pros-
ate cancer from 1990 to 2004.4-6 However, not only is
here is a growing appreciation that widespread PSA
creening also results in overdiagnosis of a substantial
ortion of prostate cancers,6-8 but also, there is some
ecent evidence that death rates, albeit very low, do not
iffer significantly in nonscreened vs screened popula-
ions.9 These controversies underlie the critical need for
etter predictive tools or biomarkers that will aid clini-
ians in the discrimination of tumors that warrant treat-
ent and those that fall into the category of overdiag-
osis.
ATIONALE FOR ACTIVE SURVEILLANCE
ptimal management of newly diagnosed, clinically lo-
alized prostate cancers remains controversial. Therapy
ptions include various forms of radiation or surgery with
urative intent, surveillance with or without delayed
ntervention, systemic therapy, most commonly andro-
en deprivation, or newly emerging focal ablative thera-
ies. Surgery and radiation, while potentially highly cur-
tive in selected patients, are associated with various well
stablished and significant side effects such as inconti-
ence, erectile dysfunction, bowel dysfunction, and lower
rinary tract symptoms. Active surveillance is a disease
anagement method that offers selective delayed radical
ntervention on indication of disease progression as de-
ned by the rate of rise of PSA and/or results of repeat
rostate biopsy. This approach began to be used as a
anagement plan in selected patients with clinically
ocalized prostate cancer in the early to mid 1990s.10 It
uilt upon watchful waiting, which has long been recog-
ized as an approach to manage some cancers, and has
een demonstrated to have excellent long-term results in
0090-4295 407
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4elected patients.11 Active surveillance, which is some-
imes called “expectant management with curative in-
ent” differs from the more conventional method of
watchful waiting,” a policy of comparatively lax obser-
ation using palliative treatment for symptomatic pro-
ression.12 The aim of active surveillance is to identify
atients for curative treatment at the first sign of subclin-
cal progression, long before any symptoms or overt signs
f tumor progression are evident.
The challenge of managing localized prostate cancer is
n distinguishing the patients with clinically relevant
ancers, who may benefit from immediate radical inter-
ention, from the remainder who do not need interven-
ion. Several variables, including PSA level and kinetics,
iopsy primary and secondary Gleason score, extent of
isease on biopsy, and clinical T-stage, are associated
ith risk of disease progression and metastasis.13,14 Al-
hough there is debate regarding the appropriate PSA
hreshold for screening, most investigators agree that
SA  10 ng/mL usually predicts more aggressive tu-
ors.15 Gleason score is also an independent prognostic
ariable that influences the outcome of prostate cancer
atients,16 and Gleason sum of 6 or lower is often used to
efine low-risk prostate cancer.17 However, analyses of
rognostic features of men who have died of prostate cancer
ndicate that one-third to one-half of men who die from
rostate cancer were diagnosed with Gleason 6 grade or
ower.11,18 None of the prognostic variables, alone or
ogether,19,20 provide sufficient specificity for identifying
ggressive disease, and currently over 90% of patients
ith newly diagnosed prostate cancer are treated.21,22
hese data demonstrate the need for biomarkers for pros-
ate cancer that complement conventional risk assess-
ent. There is a clear need for markers that can predict
rostate cancer behavior and that can segregate, with a
igh degree of specificity, diseases that may be cured with
reatment from those that are indolent and for which
mmediate treatment is unnecessary.
ESULTS OF ACTIVE SURVEILLANCE
eported outcomes from many centers that promote ac-
ive surveillance to manage prostate cancer are quite
avorable. Presently, there is no consensus on the optimal
ctive surveillance protocol, and the eligibility and treat-
ent criteria, reviewed by van As and Parker23 and
all’Era et al,17 respectively, differ among the various
enters. However, all criteria, given in Table 1, resemble
hose in the report on active surveillance from Toronto,
he study with the longest follow-up.10,25 This study
ncluded 299 participants with T1/T2a disease, Gleason
core less than or equal to 3  4, and PSA  15 ng/mL.
atients were monitored with digital rectal examination
DRE) and PSA assays every 3 months for 2 years, and
hen every 6 months if the PSA level was stable. Repeat
iopsies with 10-12 cores were repeated at 1 year, and
hen every 3 years. Patients were free to choose radical
reatment at any time, and radical treatment was recom- a
08ended if the PSA doubling time was  3 years or if the
epeat biopsies showed an upgrading to Gleason 4  3 or
igher. With a median follow-up of 5 years, 198 partic-
pants remained on surveillance and 101 patients (34%)
ad interventions. Of the 2 participants who died of
rostate cancer in the Toronto group, both had a PSA
oubling time  2 years, both were treated radically
ithin 6 months, and developed metastatic disease
ithin a year. Perhaps both of these patients had occult
etastatic disease at diagnosis and would not have ben-
fited from immediate radical treatment.25
Results from other studies are concordant, as summa-
ized in Table 1. In these reports, about one-third of men
n active surveillance received treatment, with high dis-
ase-specific survival in all groups. Retrospective analysis
f data from participants in the European Randomized
tudy of Screening for Prostate Cancer who were man-
ged expectantly, both by active surveillance and watch-
ul waiting, and who conformed to active surveillance
riteria similar to those used in the initial description of
ctive surveillance,10 are consistent with results pre-
ented in Table 1.28 Data from 616 men with a median
ollow-up of 47 months indicated a calculated prostate
ancer-specific survival of 100%, which sharply con-
rasted with the 77% overall survival. These studies, as a
hole, demonstrate that an active surveillance strategy
sing selective delayed intervention for men with low-
isk prostate cancer is feasible and is associated with low
ates of significant prostate cancer progression and death.
owever, given the often prolonged natural history of
rostate cancer, the median follow-up from these pub-
ished series remains relatively short. Until there is longer-
erm data or validation of appropriate surrogate end-
oints, results from these studies must be interpreted
ith caution.
ANDOMIZED TRIALS
F ACTIVE SURVEILLANCE
o truly confirm and validate active surveillance as a
anagement plan for clinically localized prostate cancer,
e must wait for the results from large randomized trials
omparing active surveillance with active treatment. The
candinavian Prostate Cancer Group-4 Randomized
rial that randomized 695 men with localized disease
etween radical prostatectomy and watchful waiting is
he only completed randomized trial,29 although it is
mportant to emphasize that this trial utilized watchful
aiting as opposed to active surveillance. At a median
ollow-up of both 10.8 and 12 years, random assignment
o radical prostatectomy was associated with a benefit
oth in terms of disease-specific mortality and overall
urvival. Disease-specific mortality at 12 years was 12.5%
or the surgery group and 17.9% for the watchful waiting
roup (hazard ratio 0.65, 95% confidence interval 
.45-0.94, P  .03). However, the outcome data from
his trial were based largely on clinically detected disease
nd cannot be applied to screen-detected prostate cancer.
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Table 1. Select active surveillance cohorts
Study
No.
Participants
Median
Follow-Up
(mo) Eligibility Criteria
Progression and/or Treatment
Criteria
No.
Treated
(%)
Disease-Specific
Survival (%)
No. of
Metastatic
Disease
Overall
Survival
UCSF24 321 43 PSA  10 ng/mL
Gleason sum  6 (no pattern
4 and 5)
 33% Cores involved
Clinical T1/T2a
Rising PSA (PSAV  0.75 ng/
mL/y)
Gleason sum  7 on rebiopsy
Increase in volume by biopsy
parameters
24 100 None identified 100%
Toronto10,25 299 64 PSA  10 ng/mL ( 15 ng/
mL if aged  70 years)
Gleason sum  6 [ 7 (3 
4) if aged  70 years]
Clinical T1c-T2a
PSADT  3 y
Gleason sum  7 on rebiopsy
DRE change
34 99.3 After 8 y 2 (Resulted in
2 deaths)
85%
Johns Hopkins26 407 41 PSA density  0.15 ng/mL/
cm3
Gleason sum  6 (no pattern
4 and 5)
 2 Cores involved
 50% Any 1 core involved
Clinical T1c
Gleason sum  7 on rebiopsy
(any pattern 4 or 5)
 2 Cores involved
 50% Of any 1 core involved
25 100 None reported 98%
MSK and
Baylor27
88 44 Gleason sum  7
Clinical T1-2
Score based on:
Gleason score increase
PSA velocity  0.75 ng/mL/y
Increase DRE/TRUS detected
lesion
Increase biopsy volume
35 Not reported Not reported Not reported
Royal Marsden
Hospital23
326 22 PSA  15 ng/mL
Gleason sum  7 (3  4)
 50% cores involved
 10 mm Any 1 core
Clinical T1/T2a
Life expectancy  10 y
PSA velocity  1 ng/mL/y
Gleason score  4  3 on
repeat biopsy
 50% Core involved
20 100 0 98%
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4nly 5% of prostate cancers, for example, were detected
y PSA testing, and three-quarters of enrollees had cT2
umors with extracapsular extension noted in about 50%,
hich is a substantially greater tumor volume than noted
n populations enrolled in active surveillance studies in
he United States and Canada. Accordingly, it is inter-
sting to compare the 10-year disease-specific mortality of
4% in watchful waiting arm of the Scandinavian trial to
he 8-year disease-specific mortality of 1% in the Toronto
ctive surveillance experience, discussed earlier.
There are currently 3 other randomized trials that aim
o compare active treatment with expectant management
f prostate cancer. The Prostate Cancer Intervention vs
bservation Trial, for which enrollment has been com-
leted with 731 participants, also compares radical pros-
atectomy with watchful waiting.30 An ethnically diverse
roup of patients with cancers detected through PSA-
creening were enrolled. However, if radical treatment
or all (eg, prostatectomy) turns out to be better than
adical treatment for none (eg, observation), it will beg
he question of whether treatment for a select group
ased on progression on active surveillance would be as
ffective but less morbid with similar disease-specific
ortality. The Prostate Testing for Cancer and Treat-
ent compares radical prostatectomy, external beam ra-
iotherapy, and active monitoring.31 The study aims to
nroll 2000 men, and allows active therapy for a small
ubset of men with very rapid PSA doubling time.
The Phase III Study of Active Surveillance Therapy
gainst Radical Treatment in Patients Diagnosed with
avorable Risk Prostate Cancer will compare disease-
pecific survival of patients with favorable risk prostate
ancer who have been randomly assigned, at the time of
nitial diagnosis, to radical treatment or active surveil-
ance. This trial, which opened for accrual in 2007, is the
nly randomized trial with an active surveillance proto-
ol in which participants will be offered treatment based
n prespecified biochemical, histologic, or clinical crite-
ia. Those receiving treatment, either immediately or
pon disease progression, will have a choice between
rostatectomy or radiotherapy.32 Results of this study
hould provide valuable information about whether ac-
ive surveillance is superior, equal, or inferior to active
reatment for the management of select clinically local-
zed prostate cancer.
CTIVE SURVEILLANCE AND
IOMARKERS OF AGGRESSIVE DISEASE
ctive surveillance provides the opportunity, if biospeci-
ens are collected, to evaluate candidate biomarkers that
ould be used to target treatment to men who stand to
enefit from therapy, and avoid intervention in those for
hom it is unnecessary. For example, fusion products of
he androgen-regulated TMPRSS2 gene and ETS tran-
cription factor genes, which have been identified as a
ommon translocation in a majority of prostate cancers,33ave been associated with higher risk disease features in p
10mall cohorts.34,35 However, the TMPRSS2-ERG gene
usion is not always associated with outcome,36 and fur-
her studies in the prostate tissue or urine of controlled
ohorts are necessary to determine the prognostic value
f the fusion products. Of the active surveillance studies
urrently being conducted, we are aware of only 2 that
ollect blood, urine, and tissue that may be used for
iomarker studies—the study at Royal Marsden Hospital
n the United Kingdom12,23 and the Canary Prostate
ctive Surveillance Study, described later in the text.
ANARY PROSTATE
CTIVE SURVEILLANCE
TUDY AND BIOREPOSITORY
he Canary Prostate Active Surveillance Study (PASS)
s a multicenter, prospective active surveillance study
hat is currently enrolling participants at Stanford Uni-
ersity, University of California, San Francisco, Univer-
ity of British Columbia, University of Washington, and
niversity of Texas Health Science Center at San An-
onio. The study is supported by both the Canary Foun-
ation and the Early Detection Research Network
EDRN) of the National Cancer Institute. The primary
bjective is to discover and confirm biomarkers that
redict aggressive disease as defined by prespecified his-
ologic, PSA, and clinical criteria, or outcomes based on
hose variables. Secondary objectives are to determine
he proportion of patients on active surveillance who
rogress based on defined criteria, and to determine the
linical predictors of disease progression. The study is
ecruiting patients with previously untreated, early stage
rostate cancer, regardless of date of diagnosis, who have
hosen active surveillance as a preferred management
Table 2. Summary of PASS entry and progression criteria
Eligibility
Clinical stage T1–2, NX/0, MX/0.
No previous treatment for prostate cancer (including
hormonal therapy*, radiation therapy, surgery, or
chemotherapy).
ECOG performance status 0 or 1.
Elected active surveillance as preferred management
plan for prostate cancer.
If diagnosis  1 year of entry, at least 1 biopsy with
 10 cores.
If diagnosis  1 year before entry, minimum of 2
biopsies, 1  2 years before entry.
No other malignancies except adequately treated
nonmelanoma skin cancer or superficial bladder
cancer, or solid tumors curatively treated with no
evidence of disease for  5 years.
Progression
PSA doubling time  3 years.
Any increase in Gleason grade.
Clinical progression.
* Hormonal therapy includes luteinizing hormone releasing hor-
mone (LHRH) agonists and antiandrogens, but not 5- reductase
inhibitors or testosterone.lan for prostate cancer. The eligibility criteria are given
UROLOGY 75 (2), 2010
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Un Table 2. These criteria are deliberately broad and are
esigned to allow most men who choose active surveil-
ance without confounding conditions to enroll. The
road scope of disease characteristics is likely to provide
reater insight into the natural history of prostate cancer
nd serve as the basis for a rich biospecimen resource.
Participants will be evaluated by serial DRE, serum
SA, and prostate biopsies according to the timeline
utlined in Table 3. Serum PSA measurements are per-
ormed every 3 months from the time of entry, and
hysical examinations are performed at study entry and
very 6 months from the time of enrollment. Patients
ho are diagnosed within 1 year before study entry will
ndergo repeat biopsy at the baseline visit if a biopsy with
t least 10 cores is not available, at 6-12 months from the
aseline visit, at 2 years, then every 2 years. Patients who
re diagnosed at  1 year before the baseline visit will
ndergo repeat biopsy with the following schedule: at
aseline visit if only 1 prior biopsy or if the most recent
iopsy was  2 years before the baseline visit, and then
very 2 years from the most recent biopsy. The rationale
or this schema is to ensure that initial diagnostic biopsy
dequately samples the prostate, to avoid false-negative
iagnosis of high-grade cancer, and to capture early his-
ologic progression. Patients are free to choose treatment
t any time. Progression in PASS will be defined when
atients fulfill one or more of the criteria summarized in
able 2. Biochemical progression is defined as a PSA
oubling time of  3 years, based on at least 5 separate
onsecutive measurements over a minimum of 12 months
nd maximum of 24 months. PSA values from the time of
iagnosis will be used in calculations. Histologic/Grade
rogression is any increase in tumor grade. Grade pro-
ression will be calculated from the highest existing
leason grade. Clinical progression can either be local,
efined as a stepwise increase in tumor stage by DRE or
dentification of regional or distant metastasis, as defined
y radiology, cytology, or histology at sites remote from
he prostate. Progression events will be noted by local
nvestigators, programmed in the study database, and
djudicated by the PASS Endpoints Committee. These
efinitions of disease progression are sensitive but not
ecessarily specific for disease progression. Therefore, al-
Table 3. Patient evaluation timeline
Month Entry 3 6 9
Measure
PSA x x x x
Blood x x
DRE x x
Urine (post DRE) x x
Tissue/Bx: diagnosed  1 y x* x†
Tissue/Bx: diagnosed  1 y x‡
DNA (from WBC) x
* If no biopsy with at least 10 cores.
† Biopsy performed at 6-12 months from the time of entry.
‡ If only 1 existing biopsy or if most recent biopsy  2 years befo
at enrollment, a study biopsy will be conducted 2 years from thehough active treatment will be offered to a participant i
ROLOGY 75 (2), 2010hould any of these elements be met, the participant may
pt to remain on active surveillance. If this occurs, a new
SA/stage/grade status will be assigned and further pro-
ression events will be determined using the new baseline
riteria.
A paramount objective of PASS is the formation of a
iospecimen repository with associated clinical data that
ill serve as a rich resource for biomarker and prediction
tudies. Blood and urine are collected at baseline, every
ubsequent 6 months, and, if applicable, at the time of
ntervention; blood is also collected at baseline for iso-
ation of both DNA and white blood cells for future
mmortalization (Table 3). Frozen cores from needle core
iopsies are collected, and, if a participant undergoes a
adical prostatectomy, both formalin-fixed paraffin em-
edded and fresh frozen tissue are collected. Specimens
re collected and processed according to uniform stan-
ard operating procedures at all institutions. Close ad-
erence to standard operating procedures is maintained
y in-person staff training for specimen processing and
ata collection before initiation of the study as well as
egular site visits and inspection of specimens. Data col-
ected at baseline and every subsequent 6 months include
emographics (eg, age, race and ethnicity, height and
eight, cigarette and alcohol use, family history of pros-
ate cancer), medication use, and clinical data (eg, PSA,
rostate biopsy, and cancer history) while on the study
nd from the 5 years before enrollment. In addition,
nformation on diet and supplement use is collected at
aseline using validated instruments, and changes in
upplement use are followed yearly. Study coordina-
ion and data management are conducted by the Data
anagement and Coordinating Center (DMCC) of
he EDRN. Deidentified data are stored in the Validation
tudies Information Management System,37 a secure da-
abase managed by the DMCC, and location and at-
ributes of all specimens are tracked in Validation Studies
nformation Management System. Specimens are stored
n a PASS central biorepository. Proposals from the sci-
ntific community to use PASS specimens to interrogate
iomarkers will be reviewed by the PASS Biomarker
eview Committee.
The primary objective for developing the PASS repos-
12 15 18 21 24 27 // Tx.
x x x x x x
x x x x
x x x
x x x x
x x
x
try and number of previous biopsies  2; if biopsy not performed
recent biopsy, rounded to nearest 3-month study visit.re entory is to discover and/or confirm biomarkers that are
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4redictive of progressive and/or aggressive prostate can-
er, with an emphasis on confirmation. The sample size
nd power are therefore based on confirmation of a bi-
marker after its initial discovery. A desirable biomarker
hould have high specificity to identify the subset of
atients at high risk for progression while minimizing the
roportion of men for whom aggressive treatment is un-
ertaken. Therefore, the sensitivity of a biomarker is
valuated at 95% specificity. The threshold of a biomar-
er corresponding to 95% specificity does not have to be
refixed before the confirmation study, and it can be
stimated from PASS study data within the confirmation
tudy. The proportion of disease progression at 3 and 5
ears from diagnosis is estimated at 25% and 33%. At
5% specificity, a power of 90% is desired to confirm a
ensitivity  10% (which is unacceptable) if the true
ensitivity is 30% or better. Point estimates of sensitivity,
pecificity, and threshold as well as their 95% confidence
ntervals will be calculated. The samples size also depends
n the slope of receiver operating characteristic curve at
5% specificity, usually quite steep when specificity is
ear 100%. For PASS power analysis, a slope parameter
f 4 was used.38 On the basis of these assumptions, for a
ohort with at least 5-year follow up, this study requires
25 men with progression and 250 men without progres-
ion, for a total of 375 participants, or 1875 total person
ears of follow-up. The intent of PASS is to enroll at
east 400 participants.
ONCLUSIONS
ctive surveillance currently offers a management plan
or early stage, low-grade prostate cancer that allows
atients at minimum to defer, and possibly to completely
void, treatment and the attendant complications of such
reatment. The ability to target treatment to those who
ill benefit from it is still imperfect. An alternative
pproach to the management of men with potentially
ow-risk prostate cancers would be to use markers of
isease risk at the time of diagnosis and thereby segregate
hose who would potentially benefit from treatment from
hose for whom treatment is unnecessary. Active surveil-
ance studies such as PASS provide the opportunity to
tudy the natural history of localized prostate cancer and
o evaluate candidate biomarkers. Ultimately, with the
alidation of these markers, tens of thousands of men in
he United States alone could be spared the cost and
orbidity associated with the treatment of prostate
ancer.
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